A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
NCT ID: NCT05821777
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
25 participants
INTERVENTIONAL
2023-03-28
2025-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Study of LB-100 With Docetaxel in Solid Tumors
NCT01837667
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
NCT03422679
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
NCT06332755
A Study of LY2584702 in Participants With Advanced Cancer
NCT01394003
Safety and Efficacy of LCL161 in Patients With Solid Tumors
NCT01098838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LB101
Part 1
Part 1a participants will receive LB101 once every 2 weeks (Q2W) (28-day cycle), with a preliminary plan for 6 sequential dose levels. Part 1b will be a dose optimization and will include \>1 dose levels and/or dose schedules that have been deemed safe and tolerable in Part 1a.
Part 2
Dose regimen(s) for participants in Part 2 will be based on the results of Part 1.
LB101
Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LB101
Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent form (ICF)
* For Part 1: Participants who i). have a histologically confirmed solid tumor that is listed below and is advanced, unresectable, and/or metastatic and ii). have no standard therapy, are not candidates for available standard therapy, or have failed systemic therapy due to lack of response, progression, or intolerance:
* Non-small cell lung cancer (NSCLC), which is known to be PD L1 positive (combined positive score \[CPS\] ≥ 1 or tumor proportion score \[TPS\] ≥ 1%) after having received pembrolizumab or other analog immune checkpoint inhibitor at any stage of their prior therapy I. Subjects with PD-L1 positive NSCLC with known genomic alterations for which targeted therapy is approved are not required to have been treated with pembrolizumab, etc. but must have received such approved targeted therapy. Genomic alternations include, but are not limited to, epidermal growth factor receptor \[EGFR\] and anaplastic lymphoma kinase \[ALK\]
* Head and neck squamous cell carcinoma or cervical cancer, which is known to be PD-L1-positive, after having received immune checkpoint inhibitor at any stage of their prior therapy
* Cutaneous squamous cell cancer after having received immune checkpoint inhibitor at any stage of their prior therapy
* Colorectal cancer with low level microsatellite instability (MSI-low) and/or microsatellite stable(MSS)
* Ovarian cancer which is platinum resistant or platinum refractory, with platinum free interval of less than 6 months, and without rapidly progressing disease in the investigator's judgment
* Gastric cancer which is known to be PD-L1 positive after having received pembrolizumab or other analog immune checkpoint inhibitor at any stage of their prior therapy
* Participants have measurable disease according to RECIST v1.1
* Available archived tumor tissue sample (Part 1a)
* In Part 1a backfill cohort(s), Part 1b, and Part 2, subjects must agree to undergo baseline tumor biopsy
* Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participants have adequate hematological function
* Participants have adequate hepatic and renal function
* Participants have a baseline QT interval as corrected by Fridericia's formula \<= 480 milliseconds
* Participants with life expectancy \>= 12 weeks
* Participants have a body weight \>= 40 kilograms
* For female participants of childbearing potential:
* Negative urine or serum pregnancy test
* Willing to use 2 highly effective methods of contraception
* For male participants who can father a child:
* Willing to use 2 highly effective methods of contraception
Exclusion Criteria
a.In Part 1a backfill cohort(s), any subject with unknown PD-L1 status
* Participants with known negative PD-L1 status
* Participants with NSCLC, head and neck squamous cell carcinoma, cervical cancer, cutaneous squamous cell cancer, or gastric cancer that have NOT received checkpoint inhibitor for advanced/metastatic disease, unless such therapy is not approved for treating a subject's specific condition
* Participants who receive adjuvant systemic therapy and progressed with advanced disease within 6 months of completing treatment
* Participants who have had previous exposure to CD47 or SIRPα targeting anticancer therapy
* Participants participating in another interventional clinical study
* Participants who have ongoing side effects to any prior therapy or procedure, which have not recovered to NCI CTCAE Grade \<= 1
* Participants who have received immunosuppressive drugs within 7 days prior to the start of LB101 or systemic glucocorticoids equivalent
* Participants who have received a live attenuated vaccine within 4 weeks prior to the start of LB101. For any subject receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, the investigator will be advised to follow the vaccine label and/or local guidance
* Participants with primary brain tumors and evidence of new or progressing cerebrospinal or leptomeningeal metastases
* Participants who have a history of Grade ≥ 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any components of LB101
* Participants with active or suspected systemic inflammatory autoimmune diseases or with a history of documented autoimmune disease over the past 2 years
* Participants who have ongoing or active infection requiring IV anti-infective medications
* Participants with a known history of:
* Seropositivity for human immunodeficiency virus (HIV)
* Positive serology for hepatitis B, known history/positive serology for hepatitis C virus (HCV)
* Allogenic organ transplantation and/or hematopoietic stem cell transplantation
* Participants who have had a history of life-threatening treatment-related AEs with prior immunotherapy or who have not recovered from prior cancer therapy-induced AEs
* Participants with clinically significant ascites
* Participants with moderate bilateral pleural effusion or massive bilateral pleural effusion or respiratory dysfunction requiring drainage
* Participants with uncontrolled cardiovascular disease
* Participants with any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory test values that, at the discretion of the investigators are deemed ineligible to participate
* Participants with a history of other advanced solid tumor malignancies except:
* Cured malignant tumors for \> 2 years prior to enrollment and no known active disease
* Tumors with negligible risk of metastases or death
* Pregnant or lactating female participants
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LockBody Therapeutics Ltd
INDUSTRY
Centessa Pharmaceuticals (UK) Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarah Cannon Research Institute at HealthONE.
Denver, Colorado, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Sarah Cannon Research Institute at Tennessee Oncology Nashville
Nashville, Tennessee, United States
NEXT Oncology - Dallas
Irving, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003928-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
LB101-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.